Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

Inclusion Criteria: * Total body weight between 50 and 115 kg (110 and 250 lbs) * Hemoglobin (Hgb) \> 12 mg/dL * Platelet count \> 100,000/μL * Absolute neutrophil count (ANC) \> 1000/μL * Creatinine =\< institutional upper limit of normal (ULN) * Serum glutamate pyruvate transaminase (SGPT) and serum glutamic oxaloacetic transaminase (SGOT) \< 2.0 x ULN * Total bilirubin =\< ULN (participants with a higher level of bilirubin presumed due to familial metabolism will be considered on an individual basis) * Life expectancy greater than 3 years * Participants must agree to use adequate contraception (barrier method of birth control; abstinence) from time of screening until study completion (i.e., for at least 2 weeks after last dose of study drug) * Ability to understand and the willingness to sign a written informed consent document * Agree to refrain from use of selenium (Se) supplements (other than the 100 mcg dose common in multivitamins) or Se-containing drugs while on study between 30 days before study drug initiation and Day 84 Exclusion Criteria: * Not willing to remain at Roswell Park Cancer Institute (RPCI), and in follow up, as required * Presence of medical conditions which, in the opinion of the investigator, would place either the participant or the integrity of the data at risk * Serum creatinine \> ULN, SGOT or SGPT \>= 2.0 x ULN, or bilirubin \> ULN * Treatment with an investigational drug within 30 days prior to the dose of study drug * Use of selenium \[Se\] supplements greater than the 100 mcg dose common in multivitamins between 30 days before study drug initiation and Day 84 * History of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent (e.g., reaction to other Se supplements) * Participants who have donated 1 unit of blood within 30 days prior to the first dose of investigational agent * Eastern Cooperative Oncology Group (ECOG) performance status \> 1 * Diagnosed with cancer, other than non-melanoma skin cancer, in last 2 years * Under treatment for any cancer * Use of glucose-lowering agents or a condition that would make a fast from 10:00 pm the evening before until 11:00 am on days 1 and 84 hazardous * American Urological Association (AUA) total symptom score \> 10 or any individual symptom score of greater than or equal to 4 * Psychiatric illness which would prevent compliance with the intervention or would prevent the patient from providing informed consent * Medical conditions which in the opinion of the treating physician would make this protocol unreasonably hazardous for the participant